Key facts
- This page summarizes Ruty Ben Shlomi's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Oct 2026, 16:15.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the "Reverse Stock Split"). The amount of securities reported on this Form 3 has been adjusted to reflect the Reverse Stock Split.
Footnote F2
The Pre-Funded Warrants remain exercisable until fully exercised.
Footnote F3
The Milestone Pre-Funded Warrants become exercisable upon their issuance, subject to the achievement of specified business milestones, and remain exercisable until fully exercised. The Milestone Pre-Funded Warrants are exercisable for up to an aggregate of 3,999,446 ordinary shares, no par value, of the Issuer (the "Ordinary Shares"), with the first tranche, covering 441,683 Ordinary Shares, becoming exercisable upon achievement of the first milestone; the second tranche, covering 1,718,726 Ordinary Shares, becoming exercisable upon achievement of the second milestone; and the third tranche, covering 1,839,037 Ordinary Shares, becoming exercisable upon achievement of the third milestone, in each case subject to the terms and conditions of the Milestone Pre-Funded Warrants.